Pharmaceuticals

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

An award for an AI search tool seems routine, but Ask Ella signals a deeper rewiring of the life sciences industry, turning data drudgery into strategic speed.

A novel membrane technology promises to speed up production of next-gen medicines by solving a critical, energy-intensive bottleneck in pharmaceutical manufacturing.

ZOIA and Meta Healthcare's alliance brings a ready-to-use liquid nutrition to the US, promising to ease the daily burden for those with a rare metabolic disorder.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

As the GLP-1 market booms, Vivani Medical's new semaglutide implant promises a 'set-and-forget' solution to the adherence crisis plaguing weight-loss drugs.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

Tiziana Life Sciences has dosed the final patient in a key trial for its nasal MS drug, foralumab. With data imminent, this could be a breakthrough for an untreatable form of the disease.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.

A landmark publication in The Lancet unveils AC01, a novel oral drug that safely improves heart function, offering a beacon of hope for millions with heart failure.

A landmark survey reveals a stunning bipartisan mandate on reproductive health, showing a vast majority of Republican voters support protecting access to EC.

A landmark FDA approval for Merck's KEYTRUDA and Gilead's Trodelvy creates a powerful new first-line treatment for advanced triple-negative breast cancer.

Oblenio Bio's oversubscribed Series B will advance a novel tri-specific T-cell engager, aiming to reset the immune system without harsh side effects.

ProQR Therapeutics secures a crucial $59.2M, extending its runway and gaining a powerful endorsement from partner Eli Lilly for its Axiomer RNA editing platform.

A new CMS program offers seniors blockbuster obesity drugs for $50. But this temporary fix raises profound questions about cost, access, and our healthcare future.

Insmed and EMBARC's 3,000-patient study of brensocatib aims to do more than treat a chronic lung disease—it aims to fundamentally alter its course.

Transgene unveils a scalable mpox vaccine using its cancer immunotherapy tech. Can this strategic pivot disrupt the market and fix global supply gaps?

A new license for C-Ray Therapeutics is more than a permit; it's a key move in Beijing's strategy to dominate the high-stakes radiopharmaceutical market.